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Abstract 
 
Most patients with end stage renal disease (ESRD) are supported with maintenance haemodialysis 
(HD) and this has been the case for many years. Recent improvements in water quality have led to 
the increased use of high-flux HD and more recently of online-haemodiafiltration (HDF). HDF has 
been promoted by some clinicians and by renal industry as potentially offering improved clinical and 
quality of life outcomes for patients over conventional HD. However, despite such benefits making 
theoretical sense very few studies of the use of HDF as compared to HD (especially high-flux HD) 
have been able to demonstrate any significant benefit for the therapy. This article reviews the most 
recent research that has compared HDF and HD and has identified that the evidence for the benefit of 
HDF remains elusive. This article, therefore, concludes that there is currently still not sufficient 
evidence from the research to support the contention that HDF confers benefits to patients over 
conventional HD and thereby no compelling evidence to justify its widespread use as a preferred 
form of treatment. 
 
Introduction 
 
Most patients in the United Kingdom (UK) and Europe who are treated for end stage renal disease 
(ESRD) are treated with haemodialysis (HD) (ERA-EDTA Registry 2010). In recent years, as more 
and more dialysis centres have improved the quality of their water supplies and manufacturers have 
improved and reduced the cost of larger pore dialysers this treatment has increasingly been high flux 
HD with the aim of removing greater proportions of middle-sized molecules such as phosphate. 
There is now a drive led by some clinicians and to a certain extent manufacturers of dialysis 
equipment to go one stage further and instead treat patients with haemodiafiltration (HDF), with the 
expectation that patient clinical outcomes, especially in respect of clinical outcomes, but also for 
quality of life indicators will be improved. However, despite enthusiasm for HDF in some circles the 
Holy Grail of reliable evidence from clinical trials supporting its increased use remains elusive. This 
article will describe the mechanism of HDF and review some of the more recent research within the 
field of HDF and thereby discuss the current evidence for the wide scale adoption of the therapy. 
Conclusions will be drawn as to the current state of evidence for or against the promotion of HDF as 
a standard therapy for ESRD in light of the research evidence presented. 
 
 
Background 
 
Standard maintenance HD relies mainly on diffusion across a semi-permeable membrane in order to 
clear solutes from the patient’s blood. Small amounts of solute are also cleared through convective 
processes as dissolved material in the ultrafiltrate, but this is limited due to relatively low 
ultrafiltration (UF) volumes. HDF it is proposed improves solute clearance, especially for middle-
molecule solutes such as phosphate, by greatly increasing the convective component of the 
procedure. To achieve this increased convective flow HDF works to artificially increase UF rates by 
infusing a replacement fluid into the extracorporeal circuit. The replacement (or substitution) fluid 
may be infused immediately prior to the dialyser (predilution HDF) or after the dialyser (postdilution 
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HDF). In order to facilitate the large convective volumes and increased removal of middle-molecule 
solutes it is necessary to use high-flux dialysers with increased pore sizes. Because modern on-line 
HDF systems generate the replacement fluid using the dialysis water supply the system requires very 
high levels of water purification to minimise the risk of toxins or infective agents from the water 
supply entering the patient’s bloodstream (Mahon et al 2013). The process of HDF is summarised 
graphically in figure 1.  
 
The prevalence of HDF as a therapy varies widely, ranging between 0.3 and 232 per million of 
population within Europe (ERA-EDTA Registry 2010) with similar variation reported in other 
jurisdictions (ANZDATA 2012). In many areas it remains unavailable to any patients, some centres 
utilise a combination of HD and HDF, often based upon locally determined patient criteria or trial 
and error as to what suits patients best. Some centres have adopted HDF as their standard treatment. 
Nephrologists according to Locatelli et al (2017) have cited dialysis-related amyloidosis, 
polyneuropathy, haemodynamic instability and longer life-expectancy as ‘strong indicators’ for 
prescribing HDF rather than HD. 
 
In HDF the addition of the replacement or substitution fluid results in dilution of the blood in the 
dialyser (especially predilution HDF) which in turn reduces the concentration gradient between the 
blood and dialysate compartments thereby reducing the effectiveness of diffusion somewhat. This is 
generally more than compensated for, however, by maximising the levels of replacement fluid and 
therefore rates of convective transport (Thomas 2014). The interaction between convection and 
diffusion in HDF does not, therefore, produce a simple additive effect and there is often a trade-off 
between the higher rate of removal of larger molecules sought and a reduced diffusion rate of often 
smaller molecules. 
 
The claimed rationale for HDF is that its use will not only improve solute clearance in patients, 
especially of phosphate and other middle molecules but also that it will help to reduce the severity of 
longer-term side-effects of HD such as hyperphosphataemia, hypertension and cardio-vascular 
disease (CVD)(Davenport et al 2010). It is also postulated that HDF will help with the problem of 
residual syndrome whereby the accumulation of dialyzable solutes has been shown to cause 
increased morbidity and mortality in long-term HD patients (Nagaoka et al 2011).  
 
A key limiting factor to the effective use of HDF therapies derives from the high levels of trans-
membrane pressure (TMP) generated by the infusion of the replacement fluid. For example in post-
dilution HDF the recommended replacement fluid flow of upto 25% of the overall blood flow can 
create problems with high TMP, even with appropriate high-flux dialysers (Thomas 2014).  
Switching to predilution HDF can help solve this problem, but adding the fluid before the dialyser 
significantly reduces the solute concentration of the blood in the dialyser thereby reducing diffusion 
rates even further. Attempts are made to counter this by achieving higher rates of convection, but this 
tends to mean the predilution HDF requires approximately double the rate of replacement fluid 
(Thomas 2014). 
 
A further limiting factor on patient suitability for HDF is the need that the therapy, to be effective, 
requires dialysis blood flows of around 350ml/min or above. This makes the therapy less suitable for 
patients with sub-optimal vascular access or cardio-vascular complications that preclude high blood 
flow rates (Thomas 2014). 
 
Post-dilution haemodiafiltration offers the most effective removal of middle molecular solutes but 
highest efficiencies are often limited by increased blood viscosity and associated clotting. For this 
reason patients’ anticoagulation doses will often need to be increased if they are switched to HDF, 
this may also preclude the therapy as a viable option for some patient groups (Thomas 2014). 
Clotting in the dialyser and associated rises in protein concentration can result in further increasing 
TMP and increasingly impaired removal of solutes. Predilution HDF partially overcomes this 
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problem, but at the price of affecting the overall efficiency of this method as a consequence of 
diminished solute concentrations (Nagaoka et al 2011). 
 
By joining both modalities in what is termed mixed HDF, it is claimed that higher therapeutic benefit 
can be achieved with reduced levels of intradialytic complications (Susantitaphong et al 2012). In 
mixed HDF, a feedback system automatically maintains constant haemodynamic conditions adjusted 
to the characteristics of modern high-flux dialysers. It is claimed that by better preserving the 
hydraulic characteristics of the dialyser, it is possible to achieve greater substitution volumes and 
thus higher ultrafiltration. This results in significantly higher convective removal of small and middle 
molecule uremic toxins while minimising albumin loss that could compromise the nutritional status 
of patients (Pedrini et al 2006). The online feedback system automatically adjusts and controls the 
infusion rate between pre-dilution and post-dilution treatment and the total infusion volume as a sum 
of both. The system also takes into account flow conditions, internal pressures, such as Arterial and 
Venous pressure changes and the permeability of the dialyser (TMP) during the treatment. Mixed 
HDF is, therefore, considered by some as an innovation that improves patient outcomes by providing 
a high fluid exchange enhancing the removal of small and middle molecular uraemic toxins and 
claims are made for improved patients’ quality of life and reduced morbidity associated with 
hyperphosphataemia and CVD (Susantitaphong et al 2012).  
 
HDF Evidence Base 
 
Despite considerable theory underpinning the rationale, evidence for the increased effectiveness of 
HDF over high-flux or even standard HD in removing larger molecule solutes has been limited and 
evidence for overall patient benefits is patchy at best. European Best Practice Guidelines on 
Haemodialysis (Tattersall et al 2007) suggest consideration of HDF as a means of delaying long-term 
complications of dialysis and also recommend keeping replacement fluid volumes as high as 
possible. 
 
The largest single study into HDF was the ESHOL Study (Maduel et al 2013). This study involved 
over 900 patients in 27 Catalonian dialysis units and the researchers randomised patients to either 
HD or on-line HDF, dialysis time did not differ between the two groups but blood and dialysate flow 
rates were higher in the HDF group. Most of the HD patients were treated using high-flux dialysers. 
Patients were followed up for an average of 2 years. The study reported a 30% reduction in all-cause 
mortality for HDF compared to HD, especially with respect of risk of stroke or infectious mortality. 
The authors cite the small number of patients receiving low-flux HD as a potential weakness of the 
study, but seem to make no comment as to the possible effect on the findings of the higher blood and 
dialysate flow rates of the patients randomised to the HDF group. The ESHOL Study concluded that 
HDF reduced all-cause mortality when compared to conventional HD treatment. 
 
Nistor et al (2015) undertook a Cochrane review of twenty separate HDF studies (randomised control 
trials (RCTs) and quasi-RCTs) comprising a total of nearly 3500 patients. The ESHOL Study cited 
above was included in the review. The review followed up an earlier one (Rabindranath et al 2006) 
which was funded by the National Kidney Research Fund (UK) which concluded there was 
insufficient evidence to recommend HDF therapies as opposed to conventional HD. The studies 
reviewed by Nistor et al were very heterogeneous and prone to selection bias arising out of patient 
suitability issues. Differences also arose on the basis of whether patients randomised to HDF were 
compared to patients receiving high-flux or low-flux HD – some papers failed to specify.  Bias was 
identified as a problem in a significant number of the studies reviewed arising out of incomplete 
outcome data, selective reporting and in a number of cases commercial sponsorship on authorship, 
data management or both. 
 
The Nistor et al (2015) review found that HDF did result in a significant reduction in death from 
cardiovascular causes when compared to HD, which they quantified in terms of HDF potentially 
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preventing 25 cardiovascular deaths for every 1000 patients treated when compared to HD. However, 
when the reviewers looked at all-cause mortality they found no significant advantage for HDF over 
HD therapy. In terms of morbidity Nistor et al also found no significant advantage to HDF over HD 
in terms of non-fatal cardiovascular events or hospitalisation rates, though analysis of this was 
hampered by the ten year spread of the papers reviewed which could have biased some 
hospitalisation rates. Nistor et al found no significant differences across the studies in systolic blood 
pressure rates either pre/post treatment or intradialytic, though there have been studies that have 
claimed this as a positive outcome of HDF. Only a minority (8) of the studies reviewed by Nistor et 
al undertook any analysis of patient quality of life (QoL) measures and their findings based on this 
limited data were that there was no significant evidence of any QoL advantage for HDF over 
conventional HD therapies. Finally, the Nistor review did find some evidence for increased urea 
clearance in patients receiving HDF evidenced by increased Kt/V scores but there was no real 
evidence to link this to overall improvements in patient outcomes. 
 
More recent analysis of DOPPS data by Locatelli et al (2017) has also concluded that HDF could not 
demonstrate improved patient survival over conventional HD therapy. This was a cohort study of 
patients aged 18 or over and receiving in-centre HD or HDF. Patients were randomly sampled from 
20 HD facilities in each of seven European countries. 23% of the patients in the cohort were 
receiving HDF. Importantly, in their review of the literature Locatelli et al (2017) also acknowledge 
that little reliable data exists to confer any significant benefit in terms of mortality or morbidity to 
HDF over conventional HD. 
 
Many individual studies, however, do cite evidence the HDF patients are generally healthier overall 
then HD patients. Generally, these data, however, often lose significance once selection bias of 
patients chosen for HDF therapy are removed (Locatelli et al 2017). There is evidence from a 
number of individual studies that HDF can be beneficial for individual patients (Davenport et al 
2010, Oates et al 2011, Maduell et al 2013, Dey et al 2015, Hill et al 2017) and for this reason many 
units have made the therapy available to increasing numbers of HD patients in recent years. Most 
commonly reported benefits of HDF in these studies include; improved haemodynamic stability 
during treatment, improved blood pressure control, improved dialysis clearance (Kt/V), improved 
phosphate control (sometime with ability to reduce dose of phosphate binders) and often qualitative 
indications of improved quality of life. Susantitaphong et al (2012) claim that mixed HDF yields 
increased patient longevity with improved quality of life as well as reduced rates of CVD and 
hypertension. Cost savings are also claimed on the basis that fewer dialysers and dialysis circuits 
need replacing due to clotting episodes. It must be stated, however, that this study was conducted on 
only twelve patients in one centre. They state in their paper that more, larger scale, research is needed 
into the method but as yet no independent studies have been published to this effect. Certainly it is 
the author’s experience that HDF has been beneficial for individual patients, but this is of course 
merely anecdotal evidence and no attempt can be made to ascribe cause and effect. 
 
Conclusion 
 
Despite the theoretical basis for expecting improved patient outcomes from HDF over conventional 
HD the actual evidence for this from the quite considerable number of trials undertaken that compare 
the two therapies have thus far failed to demonstrate any real patient benefit in terms of all-cause 
mortality, morbidity or quality of life. The Cochrane Review undertaken by Nistor et al (2015) 
supports this conclusion and could only find statistically significant evidence for patient 
improvement with respect to reduced mortality from CVD for patients receiving HDF. These 
findings have been replicated in the more recent large scale cohort study of DOPPS data completed 
by Locatelli et al (2017). 
 
HDF does however continue to be promoted as a therapy improvement over HD by some clinicians 
and, significantly, manufacturers of dialysis equipment. In many cases the enthusiasm evinced by 
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clinicians involved in dialysis relates to personal and often anecdotal evidence that it is claimed 
shows the advantage of the therapy for certain individuals. It is the conclusion of this review that, 
whilst it may be very reasonable to transfer individual patients onto HDF if there is a clinical benefit 
to the individual there is, as yet, no convincing case for large scale migration of patients, or indeed 
whole units over to HDF. In many cases the cost differential between HDF and HD has declined in 
recent years and the provision of ultrapure water supplies is much more general than in the past and 
so it could be argued that a mixed provision of HDF and HD within units is the most appropriate 
approach in order to facilitate selection of patients to one or the other on the basis on individual 
patient circumstance. 
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Figure 1. HDF Process 
